Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities
Ahmad et al.,
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series..,
doi:10.1101/2020.05.18.20066902 (Preprint)
54 patients in long term care facilities. 6% death with HCQ+AZ compared to 22% using a naive indirect comparison.
Ahmad et al., 18 May 2020, preprint, 5 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.05.18.20066902; this version posted May 22, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience
from Case Series of 54 Patients in Long-Term Care Facilities
Imtiaz Ahmad, MD, MPH, FCCP1
Mohammud Alam, MD2
Ryan Saadi, MD, MPH3,6
Saborny Mahmud4
Emily Saadi, BS5
1
Allergy, Sleep & Lung Care, 21st Century Oncology, Fort Myers, FL
2
Infectious Disease Specialist, Cordial Medical PC, Farmingdale, NY
3
Center for Market Access and Medical Innovation, Warren, NJ
4
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
5
Yale University, School of Public Health, New Haven, CT
6
Quantaira Health, New York, NY
Corresponding author : Imtiaz Ahmad, MD, Allergy, Sleep & Lung Care, 21st Century Oncology, Fort
Myers, FL. email : iahmad02017@gmail.com
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.05.18.20066902; this version posted May 22, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Abstract:
Importance: Patients in long-term care facilities (LTCF) are at a high-risk of contracting COVID-19 due
to advanced age and multiple comorbidities. Without effective treatments, outbreaks in such facilities will
become commonplace and will result in severe morbidity and mortality. The effectiveness of doxycycline
(DOXY) and hydroxychloroquine (HCQ) combination therapy in high risk COVID-19 patients in longterm care facilities is not yet understood.
Objective: The goal of this analysis is to describe outcomes after use of DOXY-HCQ combination in
high-risk COVID-19 patients in LTCF.
Design: Case-series analysis.
Setting: Three (3) LTCFs in New York.
Participants: From March 19 to March 30, 2020, fifty-four (54) patients, residents of three (3) LTCFs in
New York and diagnosed (confirmed or presumed) with COVID-19, were included in this analysis.
Exposure: All patients who were diagnosed (confirmed or presumed) with COVID-19 received DOXYHCQ combination therapy along with standard of care.
Main Outcomes and Measures: Patients characteristics, clinical recovery, radiological improvements,
medication side-effects, hospital transfer, and death were assessed as outcome measures.
Results: A series of fifty-four (54) high-risk patients, who developed a sudden onset of fever, cough, and
shortness of breath (SOB) and were diagnosed or presumed to have COVID-19, were started with a
combination of DOXY-HCQ and 85% (n=46) patients showed clinical recovery defined as: resolution of
medRxiv preprint doi: https://doi.org/10.1101/2020.05.18.20066902; this version posted May 22, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
fever and SOB, or a return to baseline setting if..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit